For 30 years, the American Kidney Fund Clinical Scientist in Nephrology (CSN) fellowship program has funded researchers whose work is designed to improve diagnosis, treatment and outcomes for patients living with chronic kidney disease (CKD) and has promoted clinical research in nephrology. Our CSN fellows conduct prevention and outcomes research while receiving advanced training in essential skills such as medical ethics, biostatistics and epidemiology.
The Clinical Scientist in Nephrology program has trained some of nephrology's brightest scholars who have gone on to become leaders in the field and mentors to new generations of scientists studying kidney disease. Many former CSN fellows have conducted groundbreaking research that advances knowledge and treatment of kidney disease.
A Clinical Scientist in Nephrology fellowship may be granted yearly, with a maximum duration of two years for each fellowship. The maximum level of funding of $80,000 per year shall be used principally to support the candidate and his or her career development. This sum is expected to cover the individual fellow's salary (not to exceed $55,000) as well as training-related expenses.
Applications for the 2019-2020 Clinical Scientist in Nephrology Program are now closed. Please direct all inquiries to Professional Education at email@example.com or 800.638.8299. Read the announcement about our 2019-2020 Clinical Scientist in Nephrology fellows.
Meet the current CSN fellow
Katherine Wang, MD
Dr. Katherine Wang is currently a second-year nephrology fellow at Stanford University. She completed her undergraduate degree at the University of Rochester and her medical school and residency training in internal medicine at Albany Medical College.
As the 2018-2019 American Kidney Fund Clinical Scientist in Nephrology fellow, Dr. Wang’s research project is entitled SPRINTing to intensive blood pressure targets: when, for whom, and how?, will be an evaluation of the achievement of intensive blood pressure control in the Systolic Blood Pressure Intervention Trial (SPRINT).
“I am enthusiastic and earnest about this opportunity. I wholly believe in the American Kidney Fund’s commitment to fostering healthcare access, health literacy and prevention/progression of kidney disease,” said Dr. Wang.
Dr. Wang envisions an enriching career serving as an academic nephrologist. Her major interests are focused on improving hypertension outcomes, particularly in patients suffering with chronic kidney disease.